Pancreatic enzymes, what the drug manufacturing company says after Fedez shortage alarm

L'company producing drugs based on pancreatic enzymes , for which a shortage situation persists – as underlined by Fedez – is working to resolve the problem. This is explained by the American Viatris which distributes the medicines in Italy, produced by the US group Abbott.

The note

“Viatris – we read in a company statement on the shortcomings issue – is the holder of the marketing authorization and the distributor of Creon* (pancrelipase) in Italy, while the manufacturer of Creon is Abbott. We have received indication from manufacturer of the drug, Abbott, of some difficulties in the supply of Creon. The supply difficulties – it is specified – are due to the high demand at a global level. These difficulties are not linked to quality, safety or efficacy issues relating to the production of Creon. In compliance with the applicable legislation, we have communicated to the Italian Medicines Agency (Aifa) that the difficulties in supply could continue until 31 December 2025 – recalls the note – and we have undertaken the commitment to communicate any variation in a manner timely”. Highlights Viatris: “We are in daily contact with the manufacturing company to mitigate supply difficulties and reduce the impact on patients. Abbott has assured us that it is taking all necessary measures to make Creon available, so as to minimize the impact on patients”.

“Furthermore – adds the distributor – in agreement with Aifa we have sent to over 60 thousand doctors, patient associations and scientific societies an 'Important information note on Creon and Creonipe (pancrelipase)', also available on the Aifa website, which contains information on supply difficulties and proposed mitigation actions, in order to support patient management. Inside the note and on the Viatris website there are also the company contacts to which doctors, pharmacists and patients can contact for further information We cannot provide – the company points out – any specific recommendations regarding the treatment of individual patients. Patients are invited to contact their doctor to discuss treatment options based on their specific needs and clinical history.” .